Current HIV/AIDS Reports

, Volume 2, Issue 3, pp 122–126 | Cite as

Managing hepatitis B coinfection in HIV-infected patients

  • Marion G. Peters
Article

Abstract

Since viral hepatitis is one of the most common causes of morbidity and mortality in HIV, it is critical to recognize and treat these patients appropriately. Hepatitis B infection is particularly difficult to manage as it changes with shifts in immune status. Inactive infection may flare up with restoration of CD4 cell count. In addition, many drugs used to treat HIV are also active against hepatitis B. Thus, patients may require therapy for both diseases or only for hepatitis B. The practicing physician must be aware of which drug to use with antiretrovirals and which can be used for hepatitis B alone. Current therapies for HIV that have hepatitis B activity include lamivudine, emtricitabine, and tenofovir. Therapies for hepatitis B without HIV activity are adefovir and entecavir. The major advances in the past year include emerging data on epidemiology, occult infection, genotypes, and newer therapies. Long-term management of hepatitis B includes monitoring for hepatocellular carcinoma. Two recent consensus conferences have provided excellent reviews of management of coinfection [1•,2].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Alberti A, Clumeck N, Collins S, et al.: Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005, 42:615–624. This is an excellent and timely review of coinfection with respect to therapy.PubMedCrossRefGoogle Scholar
  2. 2.
    Soriano V, Miro JM, Garcia-Samaniego J, et al.: Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. J Viral Hepat 2004, 11:2–17.PubMedCrossRefGoogle Scholar
  3. 3.
    Locarnini S: Molecular virology of hepatitis B virus. Semin Liver Dis 2004, 24(Suppl 1):3–10. Basic science and an overview of the virus are covered in this review.PubMedCrossRefGoogle Scholar
  4. 4.
    Hadziyannis SJ, Papatheodoridis GV, Vassilopoulos D: Treatment of HBeAg-negative chronic hepatitis B. Semin Liver Dis 2003, 23:81–88. Critical evaluation of the importance of this increasingly common variant is highlighted.PubMedCrossRefGoogle Scholar
  5. 5.
    Kao JH, Chen PJ, Lai MY, Chen DS: Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastro 2000, 118:554–559. This is one of the first papers outlining the importance of genotypes in HBV.CrossRefGoogle Scholar
  6. 6.
    Kao JH, Chen PJ, Lai MY, Chen DS: Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastro 2003, 124:327–334.CrossRefGoogle Scholar
  7. 7.
    Sanchez-Tapias JM, Costa J, Mas A, et al.: Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastro 2002, 123:1848–1856.CrossRefGoogle Scholar
  8. 8.
    Westland C, Delaney W, Yang H, et al.: Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastro 2003, 125:107–116.CrossRefGoogle Scholar
  9. 9.
    Lai CL, Ratziu V, Yuen MF, Poynard T: Viral hepatitis B. Lancet 2003, 362:2089–2094.PubMedCrossRefGoogle Scholar
  10. 10.
    Solomon L, Flynn C, Muck K, Vertefeuille J: Prevalence of HIV, syphilis, hepatitis B, and hepatitis C among entrants to Maryland correctional facilities. J Urban Health 2004, 81:25–37.PubMedGoogle Scholar
  11. 11.
    Goedert JJ, Brown DL, Hoots K, Sherman KE: Human immunodeficiency and hepatitis virus infections and their associated conditions and treatments among people with haemophilia. Haemophilia 2004, 10(Suppl 4):205–210.PubMedCrossRefGoogle Scholar
  12. 12.
    Konopnicki D, Mocroft A, de Wit S, et al.: Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy, and increased mortality in the EuroSIDA cohort. AIDS 2005, 19:593–601.PubMedCrossRefGoogle Scholar
  13. 13.
    Thio CL: Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Semin Liver Dis 2003, 23:125–136.PubMedCrossRefGoogle Scholar
  14. 14.
    Shire NJ, Rouster SD, Rajicic N, Sherman KE: Occult Hepatitis B in HIV-Infected Patients. J Acquir Immune Defic Syndr 2004, 36:869–875.PubMedCrossRefGoogle Scholar
  15. 15.
    Hadler SC, Judson FN, O’Malley PM, et al.: Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991, 163:454–459.PubMedGoogle Scholar
  16. 16.
    Loriot MA, Marcellin P, Walker F, et al.: Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg. J Hepatol 1997, 27:251–258.PubMedCrossRefGoogle Scholar
  17. 17.
    Hofer M, Joller-Jemelka HI, Grob PJ, et al.: Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis 1998, 17:6–13.PubMedCrossRefGoogle Scholar
  18. 18.
    Toyoda H, Hayashi K, Murakami Y, et al.: Prevalence and clinical implications of occult hepatitis B viral infection in hemophilia patients in Japan. J Med Virol 2004, 73:195–199.PubMedCrossRefGoogle Scholar
  19. 19.
    Mphahlele MJ, Lukhwareni A, Burnett RJ, et al.: High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol 2005, In press.Google Scholar
  20. 20.
    Yuen MF, Yuan HJ, Wong DK, et al.: Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005, In press.Google Scholar
  21. 21.
    Bosch FX, Ribes J, Cleries R, Diaz M: Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005, 9:191–211.PubMedCrossRefGoogle Scholar
  22. 22.
    Yang HI, Lu SN, Liaw YF, et al.: Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma. N Engl J Med 2002, 347:168–174.PubMedCrossRefGoogle Scholar
  23. 23.
    McMahon BJ: The natural history of chronic hepatitis B virus infection. Semin Liver Dis 2004, 24(Suppl 1):17–21. This article provides an excellent overview of natural history.PubMedCrossRefGoogle Scholar
  24. 24.
    Bonacini M, Louie S, Bzowej N, Wohl AR: Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 2004, 18:2039–2045.PubMedCrossRefGoogle Scholar
  25. 25.
    den Brinker M, Wit FW, Wertheim-van Dillen PM, et al.: Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000, 14:2895–2902.CrossRefGoogle Scholar
  26. 26.
    Monforte AA, Bugarini R, Pezzotti P, et al.: Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr 2001, 28:114–123.CrossRefGoogle Scholar
  27. 27.
    Benhamou Y, Bochet M, Thibault V, et al.: Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999, 30:1302–1306.PubMedCrossRefGoogle Scholar
  28. 28.
    Benhamou Y: Antiretroviral therapy and HIV/hepatitis B virus coinfection. Clin Infect Dis 2004, 38(Suppl 2):S98–103.PubMedCrossRefGoogle Scholar
  29. 29.
    Janssen HL, van Zonneveld M, Senturk H, et al.: Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet 2005, 365:123–129.PubMedCrossRefGoogle Scholar
  30. 30.
    Marcellin P, Lau GK, Bonino F, et al.: Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004, 351:1206–1217.PubMedCrossRefGoogle Scholar
  31. 31.
    Cooksley WG, Piratvisuth T, Lee SD, et al.: Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003, 10:298–305.PubMedCrossRefGoogle Scholar
  32. 32.
    Quan DJ, Peters MG: Antiviral therapy: nucleotide and nucleoside analogs. Clin Liver Dis 2004, 8:371–385.PubMedCrossRefGoogle Scholar
  33. 33.
    Yao FY, Terrault NA, Freise C, et al.: Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001, 34:411–416.PubMedCrossRefGoogle Scholar
  34. 34.
    Liaw YF, Sung JJY, Chow WC, et al.: Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease. N Engl J Med 2004, 351:1521–1531.PubMedCrossRefGoogle Scholar
  35. 35.
    Benhamou Y, Bochet M, Thibault V, et al.: Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001, 358:718–723.PubMedCrossRefGoogle Scholar
  36. 36.
    Delaugerre C, Marcelin AG, Thibault V, et al.: Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob Agents Chemother 2002, 46:1586–1588.PubMedCrossRefGoogle Scholar
  37. 37.
    Locarnini S, Qi X, Arterburn S, et al.: Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB) [abstract]. Paper presented at the 40th Annual Meeting of the European Association for the Study of Liver Diseases. Paris, France; April 13–17, 2005.Google Scholar
  38. 38.
    Peters M, Anderson J, Lynch P, et al.: Tenofovir Disoproxil Fumarate is not Inferior to Adefovir Dipivoxil for the Treatment of Hepatitis B Virus in Subjects who are Co-infected with HIV: Results of ACTG A5127 [abstract]. Paper presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 22–25, 2005.Google Scholar
  39. 39.
    van Bommel F, Wunsche T, Mauss S, et al.: Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004, 40:1421–1425.PubMedCrossRefGoogle Scholar
  40. 40.
    Lai CL, Rosmawati M, Lao J, et al.: Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastro 2002, 123:1831–1838.CrossRefGoogle Scholar
  41. 41.
    Pessoa W, Gazzard B, Huang A, et al.: Entecavir in HIV/HBV-coinfected Patients: Safety and Efficacy in a Phase II Study (ETV-038) [abstract]. Paper presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 22–25, 2005.Google Scholar
  42. 42.
    Lai CL, Lim SG, Brown NA, et al.: A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 2004, 40:7190–726.CrossRefGoogle Scholar

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • Marion G. Peters
    • 1
  1. 1.Division of GastroenterologyUniversity of CaliforniaSan FranciscoUSA

Personalised recommendations